Published in:
Open Access
01-05-2014 | Poster presentation
LEDGF/p75 IN interaction inhibitors: in silico studies of an old target with novel approach
Authors:
Amit M Pant, Rupesh V Chikhale, Sunil S Menghani, Pramod B Khedekar
Published in:
BMC Infectious Diseases
|
Special Issue 3/2014
Login to get access
Excerpt
Despite development in Anti Retroviral Therapy (ART), reports of HIV infection remains in continuous momentum and a cure seems to be imaginary. Raltegravir, an Integrase (IN) inhibitor, provides some life expectancy to patients on salvage therapy. Nowadays, IN inhibitors reported with resistance and shows cross resistance to other drugs in this class. Human Lens Epithelium Derived Growth Factor (LEDGF)/p75 plays a vital role in the HIV life cycle and its importance has been shown in numerous studies. In the LEDGF/p75 IN complex, LEDGF binds to IN at a region other than the catalytic active site. Thus, we tried computationally to approach these IN-LEDGF interaction sites as a novel target in therapy. …
